Teva's Ecopipam Shows Sustained Tic Reduction In Pediatric Tourette Syndrome

Teva Pharmaceutical Industries presented new data on ecopipam, an investigational treatment for pediatric Tourette syndrome, at a medical congress. The data included safety and efficacy results from an 8-week treatment period and an ongoing open-label extension study.

Sanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.

Teva Pharmaceuticals' investigational once-monthly subcutaneous olanzapine formulation, TEV-749, showed promising results in a post hoc analysis of the phase 3 SOLARIS trial. Over half of participants achieved clinical stabilization, and more than 20% met remission criteria. The study also found no cases of post-injection delirium/sedation syndrome, potentially eliminating the need for post-injection monitoring.

Teva (TEVA) reported that 69.8% of 292 patients in a pooled analysis showed clinically meaningful tic improvement within 8 weeks of using ecopipam, an investigational treatment for pediatric Tourette syndrome. An 18-month interim analysis of an ongoing open-label extension study found a 45.6% mean reduction in tic severity scores with no new safety signals. The FDA has granted ecopipam Priority Review and Orphan Drug designation.

Teva (TEVA) reported that ecopipam, an investigational drug for Tourette syndrome, reduced pediatric tic relapse risk by 50% vs. placebo in a Phase 3 trial (HR: 0.5; P=0.008). The FDA granted Priority Review and Orphan Drug designation for its pediatric use. Common side effects included somnolence and headache, but no significant weight gain or metabolic issues were observed.

Teva Pharmaceuticals presented new data on ecopipam, an investigational treatment for pediatric Tourette syndrome, at the International Congress of Parkinson’s Disease and Movement Disorders. The data showed a 70% reduction in tics within 8 weeks and sustained efficacy over 18 months, with no new safety signals. Ecopipam is under FDA Priority Review and could be the first new therapy for Tourette syndrome in over a decade if approved. (NYSE: TEVA)